The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Amyloidosis: Pathogenesis and New Therapeutic Options
Open accessAbstract
The systemic amyloidoses are a group of complex diseases caused by tissue deposition of misfolded proteins that results in progressive organ damage. The most common type, immunoglobulin light chain amyloidosis (AL), is caused by clonal plasma cells that produce misfolded light chains. The purpose of this review is to provide up-to-date information on diagnosis and treatment options for AL amyloidosis. Early, accurate diagnosis is the key to effective therapy, and unequivocal identification of the amyloidogenic protein may require advanced technologies and expertise. Prognosis is dominated by the extent of cardiac involvement, and cardiac staging directs the choice of therapy. Treatment for AL amyloidosis is highly individualized, determined on the basis of age, organ dysfunction, and regimen toxicities, and should be guided by biomarkers of hematologic and cardiac response. Alkylator-based chemotherapy is effective in almost two thirds of patients. Novel agents are also active, and trials are ongoing to establish their optimal use. Treatment algorithms will continue to be refined through controlled trials. Advances in basic research have led to the identification of new drug targets and therapeutic approaches, which will be integrated with chemotherapy in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Self-citationGertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Self-citationDispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Self-citationCardiovascular Magnetic Resonance in Cardiac Amyloidosis
Maceira, A. M., Joshi, J., Prasad, S. K., Moon, J. C., Perugini, E., Harding, I., Sheppard, M. N., Poole-Wilson, P. A., Hawkins, P. N., & Pennell, D. J. (2005) · Circulation · doi:10.1161/01.cir.0000152819.97857.9d · Cited by 982
Vrana, J. A., Gamez, J. D., Madden, B. J., Theis, J. D., Bergen, H. R., & Dogan, A. (2009) · Blood · doi:10.1182/blood-2009-07-230722 · Cited by 904
Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., et al. (2009) · Leukemia · doi:10.1038/leu.2008.307 · Cited by 815 · cited 1×
“In that case, the FLC : ratio or the difference between involved and uninvolved free light chains should be monitored.(20)”
BackgroundSelf-citationDiagnosis and Management of the Cardiac Amyloidoses
Falk, R. H. (2005) · Circulation · doi:10.1161/circulationaha.104.489187 · Cited by 791
Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., & Therneau, T. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361702 · Cited by 688
Self-citationMisdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis
Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A., Gilbertson, J. A., Gillmore, J. D., Pepys, M. B., & Hawkins, P. N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013354 · Cited by 680
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Colby, C., Laumann, K., Zeldenrust, S. R., Leung, N., Dingli, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5724 · Cited by 1,137
Self-citationTransthyretin (TTR) Cardiac Amyloidosis
Ruberg, F. L., & Berk, J. L. (2012) · Circulation · doi:10.1161/circulationaha.111.078915 · Cited by 708
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis
Maurer, M. S., Elliott, P., Comenzo, R., Semigran, M., & Rapezzi, C. (2017) · Circulation · doi:10.1161/circulationaha.116.024438 · Cited by 492
Cibeira, M. T., Sanchorawala, V., Seldin, D. C., Quillen, K., Berk, J. L., Dember, L. M., Segal, A., Ruberg, F., Meier-Ewert, H., Andrea, N. T., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330738 · Cited by 289
Self-citationDesport, E., Bridoux, F., Sirac, C., Delbes, S., Bender, S., Fernandez, B., Quellard, N., Lacombe, C., Goujon, J.-M., Lavergne, D., et al. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-54 · Cited by 265
Li, J.-M., Xue, Z.-Q., Deng, S.-H., Luo, X.-G., Patrylo, P. R., Rose, G. W., Cai, H., Cai, Y., & Yan, X.-X. (2013) · Neurotoxicity Research · doi:10.1007/s12640-012-9355-2 · Cited by 16
Afrough, A., Saliba, R. M., Hamdi, A., El Fakih, R., Varma, A., Dinh, Y. T., Rondon, G., Cornelison, A. M., Shah, N. D., Bashir, Q., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.03.025 · Cited by 6
“The treatment include the use of conventional cytotoxic chemotherapy agents such as melphalan and cyclophosphamide in standard doses [2, 3]; immunomodulatory agens (IMiD) including thalidomide [4] and lenalidomide [5]; the proteasome inhibitor (PI) bortezomib [6] in combination with corticosteroids; and high- dose mel…”
Background
Metadata
- Authors
- Merlini, G., Seldin, D. C., & Gertz, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-10
- Volume
- 29
- Issue
- 14
- Pages
- 1924-1933
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2151246487
- Cited by
- 509
- References
- 63
- FWCI
- 17.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.